Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
Andrew Huberman talks with an a16z host about GLP-1 drugs, BPC-157, growth hormone secretagogues, melanotan and how he thinks about peptide sourcing, plus sleep tech and cortisol sensing.
With Andrew Huberman, a16z host (not named in the captions)
Key moments
Tap a moment to play the video from there.
- 1:15Why consumer health interest surgedHuberman says fitness culture, the pandemic and a sense of personal responsibility pushed people toward supplements like vitamin D, protein and creatine.
- 13:05GLP-1s and retatrutideHuberman says retatrutide can produce weight loss of up to a third of body weight and that compounding pharmacies and gray market sources already sell it. He predicts widespread, lower-dose use.
- 18:37The non-GLP peptide crazeHuberman explains what a peptide is, then separates black market, gray market, compounding pharmacy and pharma sources, and says he worries about contaminants in 99% purity vials.
- 21:29BPC-157 and its limitsHe says he knows of no adverse events with BPC-157 but that human data is minimal. He says he would not use it long term and describes local injection as seeming better than oral forms.
- 22:31Growth hormone secretagoguesHuberman describes sermorelin and related compounds as stimulating the pituitary, taken before sleep, with more human data than BPC-157 or pinealon.
- 23:33Melanotan cautionsHe says melanotan raises energy, libido and fat loss, but warns of possibly permanent skin color changes and priapism in men.
- 25:16Low-dose GLP experimentsHe says people are finding that much lower GLP doses work for them, and that some use them to reduce alcohol craving and cognitive noise. Pharma versions cost three to 10 times more, he says.
- 31:40Real-time cortisol sensingHuberman says he wants real-time cortisol measurement and argues for a large morning pulse that falls by late afternoon.
- 34:15A future peptide cocktailHe predicts a single injection or pill combining peptides within five years, as acceptance grows the way it has for vitamin D, creatine and magnesium.
What the video says
This is a wide-ranging a16z interview with Andrew Huberman. The first part covers why consumer interest in health has grown and his views on MAHA and mRNA funding. The peptide discussion sits in the middle, and the closing sections cover sleep technology, cortisol sensing, AI, longevity and his pet octopus.
On GLP-1 drugs, the host cites figures of nearly one in seven Americans taking one and 20% having tried them. Huberman says retatrutide went through phase three at Lilly and that people can lose up to a third of their body weight with some muscle sparing. He says compounding pharmacies and gray market sources already sell it, that this is not legal but not necessarily enforced, and that he expects more than half of Americans to be on GLPs in five years, probably at lower doses than prescribed. He says he has never taken a GLP himself.
The longest peptide section lays out sourcing tiers. Huberman ranks them from black market sellers, to gray market sites that label products for research use only, to compounding pharmacies, to drug company products. He says gray market vials often claim 99% purity and that he would worry about contaminants from repeated injection. On BPC-157 he says he has not heard of an adverse event and that human data is nearly absent. He says he tried it without noticing a benefit and that he would not use it long term because he worries about stimulating vascular growth near an undetected tumor. He also describes growth hormone secretagogues such as sermorelin and says they have far more human data. He describes melanotan as having possible permanent skin changes and a risk of priapism. He mentions trying pinealon for sleep, but says there is very little human data.
Later he predicts that within five years people may take a single injection or pill combining several peptides, and he frames sleep and cortisol tools as a shift from measuring the body to adjusting it. The interview ends with his octopus project and AI.
On each compound
BPC-15721:29
Huberman says he has not heard of an adverse event and that human data is essentially absent. He says he tried it without noticing any benefit, and that he avoids long-term use because he worries about vascular growth near a tumor someone might not know about.
See how your DNA reads BPC-157Retatrutide13:52
Huberman says it went through phase three at Lilly, with weight loss of up to a third of body weight and some muscle sparing. He says it is already sold through compounding and gray market sources and that Lilly is working to stop that.
See how your DNA reads RetatrutideSermorelin22:31
Huberman lists sermorelin among growth hormone secretagogues that stimulate the pituitary rather than being growth hormone itself. He says it is FDA approved for some uses and that taking it before sleep is how these are typically used.
See how your DNA reads SermorelinMelanotan II23:33
Huberman says melanotan raises energy, libido and fat loss and has human data. He cautions that skin color changes can be permanent and that men face a risk of priapism.
See how your DNA reads Melanotan IIWhat this video doesn’t settle
- Huberman's comments on BPC-157 and pinealon rest on his own experience and preclinical studies, with no human trial data cited.
- His prediction that more than half of Americans will use GLPs at lower doses is a personal estimate, and he gives no source for it.
- He says gray market vials claim 99% purity but cites no testing, so contamination concerns remain speculative in the video.
Questions this video answers
What does Huberman say about BPC-157 safety?
Huberman says he has not heard of an adverse event, even though people have injected large amounts. He still does not recommend it, and he says he worries about stimulating vascular growth near a tumor someone might not know they have.
What does Huberman say about gray market and Chinese peptides?
He says gray market sellers label products for research use only and often claim 99% purity, which leaves room for contaminants with repeated injection. He says black market products, where you may not know what is in the vial, are a separate and worse category.
What does Huberman say about retatrutide?
He says it went through phase three at Lilly and that people can lose up to a third of their body weight with some muscle sparing. He adds that it is already sold through compounding and gray market sources, and that this is not legal but not necessarily enforced.
What does Huberman say about melanotan?
He says it raises energy, libido and fat loss, but calls it very risky. He mentions possibly permanent skin color changes and a risk of priapism in men.
Does Huberman recommend growth hormone secretagogues?
He describes sermorelin, tesamorelin, ipamorelin and MK-677 as stimulating the pituitary and says they have much more human data than BPC-157. He ties that to the sourcing being clean, and he does not frame it as advice.
Video by a16z on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
